{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001659617","name":"Moleculin Biotech, Inc.","summary":"Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on hard-to-treat cancers and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline currently in a pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML). The company also develops WP1066 portfolio compounds targeting p-STAT3 and WP1122 portfolio glycolysis inhibitors. All three core technologies are substantially based on discoveries licensed from MD Anderson Cancer Center.","people":[],"products":[{"name":"Annamycin (naxtarubicin, L-Annamycin)","type":"platform","description":"Next-generation anthracycline with multilamellar lipid delivery system for R/R AML and STS lung metastases; in Phase 3 MIRACLE trial."},{"name":"WP1066 Portfolio (WP1066, WP1193, WP1220)","type":"platform","description":"Immune/transcription modulators inhibiting p-STAT3 and Regulatory T-Cells; Phase 1B/2 trial ongoing for glioblastoma."},{"name":"WP1122 Portfolio (WP1122, WP1096, WP1097)","type":"platform","description":"Glycolysis inhibitors based on 2-deoxy-D-glucose designed to target tumor energy supply and antiviral applications."},{"name":"AnnAraC","type":"platform","description":"Combination therapy of Annamycin plus Cytarabine (Ara-C) for treatment of relapsed/refractory AML."}],"partnerships":[{"partner_name":"University of Texas MD Anderson Cancer Center","partnership_type":"licensing","description":"Core technologies substantially based on discoveries made at or licensed from MD Anderson; ongoing sponsored research.","start_date":null},{"partner_name":"Northwestern University","partnership_type":"development","description":"Externally funded Phase 1B/2 trial of WP1066 oral formulation in combination with radiation for GBM.","start_date":null},{"partner_name":"Atlantic Health System","partnership_type":"development","description":"Externally funded Phase 1B/2 trial planned for Annamycin monotherapy in 3rd line pancreatic cancer, expected to begin 2026.","start_date":null}],"affiliations":[],"origin":{"leaf":"042ce4f55a7f32105b2d9d4464d4d254875f82f9d3ebe9755721a987b3ae7213","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"351a873198f63efe9377c4f0fdc1a4b564b738d32b5356107859f382c2a7bdeb","parent":"ef509d2d426d4d0cd53df0f2dd9100168576b8cd47b9f630ca7c3d8a8ea1edd0","source":"0001437749-26-008841","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}